PAVmed subsidiary Lucid Diagnostics raises $11.6M in Series B-1 preferred stock offering

PAVmed Inc.

Lucid Diagnostics, PAVmed's majority-owned subsidiary, raised ~$11.6M via Series B-1 Convertible Preferred Stock.
Sold approx 11,634 shares at $1,000/share to accredited investors; closed May 6, 2024.
Lucid filed Certificate of Designation for Series B-1 Preferred and entered Registration Rights Agreement.
Details are incorporated by reference from Lucid Diagnostics' separate 8-K filed May 7, 2024.

item 1.01 item 3.03 item 3.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.92

PAVmed Inc. entered into Subscription Agreement with certain accredited investors valued at approximately $11.6 million (effective 2024-05-01).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: approximately $11.6 million
Effective: 2024-05-01

Exact text from the filing

entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accredited investors (collectively, the “ Investors ”), which agreements provided for the sale to the Investors of approximately 11,634 shares of Lucid Diagnostics’ newly designated Series B-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series B-1 Preferred Stock ”), at a purchase price of $1,000 per share (collectively, the “ Offering ”). The gross proceeds to Lucid Diagnostics of the Offering were approximately $11.6 million.

View on SEC.gov

319 material agreements filed in the last 30 days. Browse all material agreements →

PAVmed Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-018036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.